Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.67 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.67 |
| ▸ | HTR3B | O95264 | 1/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.67 |
| ▸ | HTR3A | P46098 | 1/20 | 0.67 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.67 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.67 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | DRD4 | P21917 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.61 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16924853 | 1.00 | LMNA (0.67) | LMNASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL576454 | 1.00 | LMNA (0.67) | LMNASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL576814 | 1.00 | LMNA (0.67) | LMNASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL385012 | 1.00 | — | — | |
| SCHEMBL7258870 | 0.97 | LMNA (0.64) | LMNASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL576673 | 0.91 | LMNA (0.58) | LMNASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL14500221 | 0.91 | LMNA (0.58) | LMNASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL577708 | 0.91 | LMNA (0.58) | LMNASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL2114220 | 0.89 | LMNA (0.56) | LMNASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL11974615 | 0.89 | LMNA (0.56) | LMNASIGMAR1HTR3EHTR3BADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 617 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024879-A1 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | TWINCORE ZENTRUM FUR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH (DE) | 2022-01-27 | — | — | US | claimed |
| WO-2021262825-A2 | DISRUPTING LIPID SYNTHESIS: A NOVEL TARGET FOR BROAD-SPECTRUM HOST-DIRECTED ANTI-VIRULENCE THERAPEUTICS | GENETIC NETWORKS, LLC (US) | 2021-12-30 | — | — | WO | claimed |
| EP-3898593-A2 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | Gottfried Wilhelm Leibniz Universität Hannover (DE) | 2021-10-27 | — | — | EP | claimed |
| CN-113135835-A | Method for exciting C-C bond breaking acylation and application | 广州中医药大学(广州中医药研究院) | 2021-07-20 | — | — | CN | claimed |
| WO-2020127211-A2 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | GOTTFRIED WILHELM LEIBNIZ UNIVERSITÄT HANNOVER (DE) | 2020-06-25 | — | — | WO | claimed |
| EP-3670498-A1 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | Gottfried Wilhelm Leibniz Universität Hannover (DE) | 2020-06-24 | — | — | EP | claimed |
| CN-106981661-A | Preparation method of lithium ion battery electrode material | 南京工业大学 | 2017-07-25 | — | — | CN | claimed |
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2011-11-03 | — | — | US | claimed |
| EP-1269990-B1 | Cosmetic or dermatological composition comprising acylaminoamide derivatives | OREAL (FR) | 2010-10-13 | — | — | EP | claimed |
| EP-2010165-A2 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | Allergan, Inc. (US) | 2009-01-07 | — | — | EP | claimed |
| WO-1997018782-A1 | TREATMENT WITH CALCIUM CHANNEL BLOCKERS FOR DRUG-INDUCED HYPERSENSITIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-05-29 | — | — | WO | claimed |
| EP-0675118-A2 | Biphenylderivatives, process for their preparation and their use as medicaments | Eisai Co., Ltd. (JP) | 1995-10-04 | — | — | EP | claimed |
| US-5391552-A | Has strong antagonism against calcium with less side effects | POLA CHEMICAL INDUSTRIES, INC. (JP) | 1995-02-21 | — | — | US | claimed |
| EP-0612738-A1 | Diphenylpiperazine derivative and drug for circulatory organ containing the same | POLA CHEMICAL INDUSTRIES, INC. (JP) | 1994-08-31 | — | — | EP | claimed |
| EP-0555302-A1 | METHOD OF TREATING DEMYELINATING DISEASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-18 | — | — | EP | claimed |
| EP-0549796-A1 | DIPHENYLPIPERAZINE DERIVATIVE AND DRUG FOR CIRCULATORY ORGAN CONTAINING THE SAME | POLA CHEMICAL INDUSTRIES INC (JP) | 1993-07-07 | — | — | EP | claimed |
| WO-1992007564-A2 | METHOD OF TREATING DEMYELINATING DISEASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-14 | — | — | WO | claimed |
| WO-1990006123-A1 | THERAPEUTIC USE OF CALCIUM ENTRY BLOCKERS IN RETINAL OR OPTIC NERVE DYSFUNCTION | HOUSTON BIOTECHNOLOGY INCORPORATED (US) | 1990-06-14 | — | — | WO | claimed |
| US-4481373-A | CATALYTIC OXIDATION OF OLEFINS IN PRESENCE OF TERTIARY AMINE OF AMIDE | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1984-11-06 | — | — | US | claimed |
| US-4471068-A | Process and catalyst for preparation of polyphenylene oxide | GENERAL ELECTRIC COMPANY (US) | 1984-09-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024879-A1 | COMPOUNDS FOR TREATMENT OF HEPACI VIRUS INFECTION AND METHOD FOR DETERMINING THERAPY OF HEPACI VIRUS INFECTION, IN PARTICULAR, HCV INFECTION | HAVCR2, HCCS, HELZ | LMNA 2340/4885SIGMAR1 240/4885HTR3E 451/4885 |
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | LMNA 1961/4885SIGMAR1 1095/4885HTR3E 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.